IrniCann (cannabidiol/cannabigerol) / Argent BioPharma - LARVOL DELTA

Prevalence and reasons for using cannabidiol, delta-8 tetrahydrocannabinol, cannabinol, cannabigerol, and hexahydrocannabinol among US adults. (PubMed, J Cannabis Res) - "Use of cannabinoid products is appreciable, particularly CBD and delta-8 THC. Most adults use CBD, CBN, CBG, and HHC for medical reasons, but delta-8 THC for recreation. Pain, anxiety, insomnia and arthralgia were common medical reasons for use across the different cannabinoids assessed."

Journal • CNS Disorders • Insomnia • Mood Disorders • Musculoskeletal Pain • Pain • Psychiatry • Sleep Disorder

Impact of Soil Quality on Cannabinoid and Terpenoid Content of Cannabis sativa L. (PubMed, J Med Act Plants) - "Differences in terpene composition were observed between the cultivars grown in the CF but not between those grown in CC. This is the first study to show differences in extract composition of outdoor cultivated hemp grown in different soil conditions."

Journal

Clinical and Economic Outcomes of Cannabis-Based Formulations (CBD and CBD/CBG) for Autism Spectrum Disorder (ASD): A HEOR Model Study Analysis (ISPOR-EU 2025) - "Studies highlight that CBD-rich cannabis extracts may be beneficial in ASD, but they are not without side effects. Additional analyses need to be done as a whole ."

Clinical • HEOR • Autism Spectrum Disorder • Genetic Disorders

Valorization of Thyme Combined with Phytocannabinoids as Anti-Inflammatory Agents for Skin Diseases. (PubMed, Pharmaceutics) - "Selected thyme formulations-alone or in combination with CBD/CBG-were also tested in vivo using a mouse model of acute skin inflammation. The data support the safe and effective use of Thymus mastichina-derived terpene fractions for topical anti-inflammatory applications. The synergistic effect observed with CBD and CBG suggests that combining essential oil terpenes with phytocannabinoids may offer a novel therapeutic strategy for managing inflammatory skin disorders."

Journal • Acne Vulgaris • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Psoriasis

Efficacy of different cannabinoid compounds on migraine-like responses in female rats. (PubMed, Cephalalgia) - "Altogether, these results suggest that cannabinoid compounds may represent effective alternatives for the treatment of episodic and chronic migraine."

Journal • Preclinical • CNS Disorders • Migraine • Pain • ADCYAP1

CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Milton S. Hershey Medical Center | Trial completion date: Feb 2028 ➔ May 2029 | Initiation date: Sep 2025 ➔ Feb 2026 | Trial primary completion date: Jan 2028 ➔ Feb 2029

Trial completion date • Trial initiation date • Trial primary completion date • Pain

Cannabidiol releases CB1R from A2AR repression in ischemic stroke. (PubMed, Neurobiol Dis) - "Results indicated that the formation of A2AR-CB1R heteromers increased A2AR affinity for its selective agonist CGS21680...In conclusion, CBD effects in the hypoxia of the neonate can be mediated by A2AR-CB1R complex. CBD partially blocks A2AR signalling while potentiates the neuroprotective effect of CB1R in hypoxic-ischemic conditions."

Journal • Cardiovascular • Ischemic stroke

Orally Administered CBD/CBG Hemp Extract Reduces Severity of Ulcerative Colitis and Pain in a Murine Model. (PubMed, J Clin Med) - "We also observed that CBG/CBD rich hemp extracts help reduce pain-related responses in these animals. Together, the data suggest that cannabinoid administration has the potential to be an effective alternate therapeutic option for UC management."

Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Pain • Ulcerative Colitis

CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Milton S. Hershey Medical Center

New P1 trial • Pain

Evaluation of Biophysical Parameters of the Skin of Patients With Atopic Dermatitis After Application of an Ointment Containing 30% Cannabidiol and 5% Cannabigerol. (PubMed, Clin Cosmet Investig Dermatol) - "The results we achieved included improved skin hydration, sebum level, and TEWL as well as reduced erythema in the studied areas (forearms). Our results demonstrate that topical cannabinoid therapy is effective in reducing itching and improving the quality of life of patients with AD, leading to symptom remission in some cases."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Cannabis: Zone Aspects of Raw Plant Components in Sport-A Narrative Review. (PubMed, Nutrients) - "Despite many recent studies on cannabis species, there is very little research on the beneficial effects in active athletes, especially on large groups compared to placebo. These studies may complete the current vision of this topic and clarify the hypotheses launched as discussions in this review."

Journal • Review • CNS Disorders • Psychiatry

Nav1.8, an analgesic target for nonpsychotomimetic phytocannabinoids. (PubMed, Proc Natl Acad Sci U S A) - "In particular, CBG shows significant promise due to its ability to effectively inhibit excitability of peripheral sensory neurons. These findings highlight the therapeutic potential of cannabinoids, particularly CBG, as agents that may attenuate pain via block of Nav1.8, warranting further in vivo studies."

Journal • Pain • NAV1

Role of cannabidiolic acid or the combination of cannabigerol/cannabidiol in pain modulation and welfare improvement in horses with chronic osteoarthritis. (PubMed, Front Vet Sci) - "No subject required rescue analgesia or showed any adverse effects. The results of this study showed that oral administration of both CBDA and CBG/CBD oil may promote pain reduction in adult horses affected by chronic OA."

Journal • Immunology • Musculoskeletal Pain • Osteoarthritis • Pain • Rheumatology • CD4

Exploring Cannabidiol (CBD) and Cannabigerol (CBG) Safety Profile and Skincare Potential. (PubMed, Int J Mol Sci) - "Specifically, they reduced the levels of pro-inflammatory cytokines, making them valuable in combating environmental skin damage. Overall, our results validate the safety of topical use of cannabinoids, while paving the way for further research in the beauty and personal care market as soothing agents."

Journal • Dermatology • Inflammation

Exploring the Potential of Nonpsychoactive Cannabinoids in the Development of Materials for Biomedical and Sports Applications. (PubMed, ACS Appl Bio Mater) - "The review also addresses innovative approaches to enhance NPC delivery including the use of computational tools and explores their potential in both biomedical and sports science contexts. By providing a comprehensive overview of the current state of research, this review aims to outline future directions, emphasizing the potential of NPCs in biomaterial science and regenerative medicine."

Journal • Review • Pain

Effect of Hemp Extraction Procedures on Cannabinoid and Terpenoid Composition. (PubMed, Plants (Basel)) - "This work aimed to compare cannabinoid and terpene profiles using the three primary commercial procedures, using hemp inflorescence from a CBD/CBG dominant Cannabis sativa L. cultivar. Ethanol extracts contained the most acidic cannabinoids with 3.2-4.1 mg/g of CBDA along with minor terpene levels. The resulting extracts demonstrated substantially different chemical profiles and highlight how the process used to extract hemp can play a large role in product composition and potential biological effects."

Journal

Single and Combined Effects of Cannabigerol (CBG) and Cannabidiol (CBD) in Mouse Models of Oxaliplatin-Associated Mechanical Sensitivity, Opioid Antinociception, and Naloxone-Precipitated Opioid Withdrawal. (PubMed, Biomedicines) - "We have previously demonstrated that treatment with the psychoactive CB1/CB2 cannabinoid receptor agonist Δ9-tetrahydrocannabinol (Δ9-THC) or the non-psychoactive, minor phytocannabinoid cannabidiol (CBD) can attenuate paclitaxel-induced mechanical sensitivity in a mouse model of CIPN...Most recently, it was reported that another minor cannabinoid, cannabigerol (CBG), attenuated cisplatin-associated mechanical sensitivity in mice...CBG and CBD decreased naloxone-precipitated jumping behavior alone and acted synergistically in combination, while CBG attenuated the acute antinociceptive effects of morphine and CBD. Taken together, CBG may have therapeutic effects like CBD as demonstrated in rodent models, and its interactive effects with opioids or other phytocannabinoids should continue to be characterized."

Journal • Preclinical • Pain

Modulation of Redox and Inflammatory Signaling in Human Skin Cells Using Phytocannabinoids Applied after UVA Irradiation: In Vitro Studies. (PubMed, Cells) - "Modification of antioxidant signalling (Nrf2/HO-1) through the administration of CBG+CBD has been proven to be associated with reduced proinflammatory signalling (NFκB/TNFα). Differential metabolic responses of keratinocytes and fibroblasts to the effects of the UVA and phytocannabinoids have indicated possible beneficial protective and regenerative effects of the phytocannabinoids, suggesting their possible application for the purpose of limiting the harmful impact of the UVA on skin cells."

Journal • Preclinical • Inflammation • TNFA

CHONDROPROTECTIVE AND ANALGESIC EFFECTS OF NATURAL AND SYNTHETIC CANNABINOIDS IN MURINE OSTEOARTHRITIS (OARSI 2024) - "Our recently published data showed that non-euphorigenic cannabis extract with high CBG and cannabidiol (CBD) content (CBG:CBD oil) reduces pain and slows down OA development in male mice when administered at the time of traumatic injury, resembling early OA. In this study, we aim to determine the efficacy of cannabis extracts in ongoing OA and whether the effect is sex-dependent; in addition, we will explore the possibility of an entourage effect by comparing the efficacy of natural cannabis extracts to those of pure synthetic cannabinoids. We hypothesize that CBG (pure or in cannabis extracts) possess potent analgesic effects and is chondroprotective when used during ongoing OA."

Preclinical • Immunology • Musculoskeletal Diseases • Musculoskeletal Pain • Orthopedics • Osteoarthritis • Pain • Rheumatology

Phytocannabinoids CBD, CBG, and their Derivatives CBD-HQ and CBG-A Induced In Vitro Cytotoxicity in 2D and 3D Colon Cancer Cell Models. (PubMed, Curr Issues Mol Biol) - "In this study, we tested the anticancer potential of selected cannabinoids CBD (cannabidiol) and its quinone derivative CBD-HQ (cannabidiol hydroquinone), CBG (cannabigerol) and its acid derivative CBG-A (cannabigerolic acid), as well as a combination of CBD+CBG on the colon cancer cell line SW-620. Our results suggest that cannabinoids represent an interesting research direction with great implementation potential. These preliminary results represent the beginning of research into the potential of these substances for anticancer treatment and underscore the potential for further research."

Journal • Preclinical • Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Mood Disorders • Oncology • Pain • Palliative care • Psychiatry • Solid Tumor

Antibiofilm and Immune-Modulatory Activity of Cannabidiol and Cannabigerol in Oral Environments-In Vitro Study. (PubMed, Antibiotics (Basel)) - "Both CBG and CBD inhibit S. mutans; they also moderately lower the metabolic activity of multispecies biofilms that form; however, CBD had an effect on biofilms that had already developed. This, together with the production of anti-inflammatory mediators and the maintenance of the viability of mammalian cells from the oral cavity, make these substances promising for clinical use and should be taken into account for future studies."

Journal • Preclinical • Dental Disorders • Immunology • Periodontitis • IFNG • IL4 • TGFB1

Host status and susceptibility of Cannabis sativa cultivars to root-knot nematodes. (PubMed, J Nematol) - "Root-knot nematode host status of hemp cultivars of different uses (fiber, dual, CBD/CBG) and from different regions (Europe, China, US) were evaluated in five different greenhouse trials. While no negative impact on hemp shoot growth was seen in trials where nematodes were added to pasteurized soil, a significant and visible negative effect on hemp growth was noted when two CBG hemp cultivars were planted in heavily naturally root-knot infested soil. This result indicates that hemp is not only a good host to root-knot nematodes, but also that root-knot can be a limiting factor for hemp production in Florida and other places with high abundance and pressure of root-knot nematodes."

Journal • Infectious Disease

Spray-Dried Powder Containing Cannabigerol: A New Extemporaneous Emulgel for Topical Administration. (PubMed, Pharmaceutics) - "Thermogravimetric analysis (TGA), attenuated total reflection-Fourier transformed infrared spectroscopy (ATR-FTIR), x-ray powder diffraction (XRPD), and high-performance liquid chromatography (HPLC) analyses demonstrated that the spray-drying treatment did not alter the chemical properties of CBG. This product can represent a metered-dosage form for the localized treatment of cutaneous afflictions such as acne and psoriasis."

Journal • Acne Vulgaris • Dermatology • Immunology • Psoriasis

Investigation of the cytotoxicity induced by cannabinoids on human ovarian carcinoma cells. (PubMed, Pharmacol Res Perspect) - "Both CBD and CBG induced stronger cytotoxicity than afforded by carboplatin in resistant cells. The cytotoxicity induced by CBD was not CB or CB receptor dependent in both carcinoma cells, however, CBG-induced cytotoxicity may involve CB receptor activity in cisplatin-resistant carcinoma cells...Further studies are required to investigate whether these results are translatable in the clinic. Combination therapies with conventional cancer treatments using cannabinoids are suggested."

Journal • Oncology • Ovarian Cancer • Solid Tumor • ANXA5 • CASP3 • CASP7

Proof of Concept Open Label Trial of CBD/CBG Oral Tincture in the Management of Symptoms in Adult Patients with Irritable Bowel Syndrome (ACG 2023) - "5 of the 6 patients had a reduction in pain scale from baseline using a Likert Pain Scale of 0-10. Mean pain score 6.6 at baseline and 3.7 at Day 14, a decrease of 33.4%. 1 male patient had a worse pain score Day 14 (5) than Baseline (1)."

Clinical • Gastrointestinal Disorder • Pain • Women's Health • RSPO1